Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Gout FocusRheum

Gout is a common form of inflammatory arthritis, affecting ~9.2 million adults (3.9%) in the U.S. The good news: The etiology of gout is well understood, and effective, inexpensive medications exist to treat it. However, gaps in quality of care persist. Below, explore selected content from The Rheumatologist’s collection of research reviews, case reports and clinical articles on advances in the diagnosis and management of gout. New features are added often, so check back frequently.

Gout expert Lisa Stamp, MBChB, FRACP, PhD, will sort through the research abstracts on gout accepted for presentation at ACR Convergence 2024 to bring you the most important concepts and findings.

FEATURED ARTICLE: AC&R Study Summary: TV & the Public Perception of Gout

 

Reducing Immunogenicity of Pegloticase ... Click here to view abstract videoReducing Immunogenicity of Pegloticase ... Click here to view visual abstract summary

ACR Convergence

Research Roundup: Abstract Data Presented at ACR Convergence 2021

The research presented at ACR Convergence 2021 had a broad scope. Below are details on three studies that addressed cardiovascular safety in treat-to-target strategies, phase 2 study results on the efficacy of tigulixostat and the impact of patient preference on treatment adherence. Take our quiz after you read this article. Treat to Target Abstract L06:…

Research on Diet & Gout

According to research from Yokose et al. presented at ACR Convergence 2021, regardless of genetic predisposition, diet influences a person’s risk of developing gout.1 Several recent analyses of the Global Burden of Disease (GBD) Study report a disproportionate worsening of gout burden among women, suggesting intensive dietary measures for gout prevention are indicated, especially in…

Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial

Short-term concomitant use of MMF with pegloticase was generally well tolerated in this proof-of-concept study. It was associated with a statistically significant and clinically meaningful impact on the proportion of subjects achieving and maintaining a sUA ≤6 mg/dL at 24 weeks. See the abstract with bonus video discussing the validation of proposed remission and completion criteria for the treatment of gout.

Research, Case Reports & More

Gout & Its Comorbidities

At ACR Convergence 2023, experts addressed important topics in gout research, including treating and preventing gout flares, lowering urate levels and managing comorbidities, as well as racial inequities in gout treatment, disease burden and outcomes.

Old Disease, New Tricks: A Novel Approach to Understanding Gout

SAN DIEGO—Gout has sometimes been called the disease of kings, not only because of the fact that purine-rich foods were long affordable only to wealthier individuals, but also because the disease has been around since the monarchies that existed centuries ago. However, with groundbreaking research leading to a better understanding of gout, we can now…

How to Reduce Gout Flares

SAN DIEGO—If patients with gout keep their serum urate (SU) levels very low with urate-lowering therapy (ULT), they have fewer flares, according to a research abstract presented at ACR Convergence 2023.

Gout & Excess Risk of Severe SARS-CoV-2 Infection

In this large, population-based study, Xie et al. found that the risks of SARS-CoV-2 infection, 30-day hospitalization and 30-day death were higher among individuals with gout than individuals without gout in the general population, irrespective of COVID-19 vaccination status.